2Burger RA.Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies[J].J Gynecol Oncol,2010,21(1):3-11.
3Han LY,Kipps E,Kaye SB.Current treatment and clinical trials in ovarian cancer[J].Expert Opin Investig Drugs,2010,19(4):521-534.
4Yen MS,Twu NF,Lai CR,et al.Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer[J].Gynecol Oncol,2009,114(3):415-419.
5Helm CW,Richard SD,Pan J,et al.Hyperthermic intraperitoneal chemotherapy in ovarian cancer:First report of the HYPER-O registry[J].Int J Gynecol Cancer,2010,20(1):61-69.
6Chen ZH,Jing YJ,Song BH,et al.Chemically modified heparin inhibits in vitro L-selectin-mediated human ovarian carcinoma cell adhesion[J].Int J Gynecol Cancer,2009,19(4):540-546.
3Zhang Dong-mei,Holmes W F,Wu Shu-jian,et al.Retinoids and ovarian cancer[ J ].J Cell Physiol,2000,185:1-20.
4Guruswamy S,Lightfoot S,Michael A G,et al.Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian tumors[ J ].J Natl Cancer Inst,2001,93:516-525.
5Miwa I,Suzuki S.An improved quantitative assay of glycogen in erythrocytes[ J].Ann Clin Biochem,2002,39:612-613.
6Gomez-Lechon M J,Ponsoda X,Castell J V.A microassay for measuring glycogen in 96-well-cultured cells[J].Anal Biochem,1996,236 (2):296-301.
7Morkve O, Learun OD. Flow cytometric measurement of p53 protein expression and DNA content in paraffin-embedded tissue from bronchial carcinomas [ J]. Cytometry, 1991, 12(5) :438-444.
8Wittekind C, Neid M. Cancer invasion and metastasis [ J ]. Oncology, 2005, 69 (1):14-16.
9Imai T, Horiuchi A, Shiozawa T, et al. Elevated expression of Ecadherin and alpha-, beta-, and gamma-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas [ J ].Hum Pathol, 2004, 35(12) :1469-1476.
10Faleiro-Bodrigues C, Macedo-Pinto I, Pereira D, et al. Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas[ J]. Ann Oncol,2004, 15(10) :1535-1542.
